tdoc-20240405

0001477449-24-000083.txt : 20240405 0001477449-24-000083.hdr.sgml : 20240405 20240405160510 ACCESSION NUMBER: 0001477449-24-000083 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240405 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240405 DATE AS OF CHANGE: 20240405 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Teladoc Health, Inc. CENTRAL INDEX KEY: 0001477449 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 043705970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37477 FILM NUMBER: 24826449 BUSINESS ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 BUSINESS PHONE: 2036352002 MAIL ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 FORMER COMPANY: FORMER CONFORMED NAME: Teladoc, Inc. DATE OF NAME CHANGE: 20091123 8-K 1 tdoc-20240405.htm 8-K tdoc-20240405

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) April 5, 2024

___________________________________

Teladoc Health, Inc.

(Exact name of registrant as specified in its charter)

___________________________________


Delaware (State or other jurisdiction of incorporation)	001-37477 (Commission File Number)	04-3705970 (I.R.S. Employer Identification No.)
2 Manhattanville Road Suite 203 Purchase, NY 10577
(Address of principal executive offices and zip code)
(203) 635-2002
(Registrant's telephone number, including area code)

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:
Title of each class	Trading Symbol	Name of each exchange on which registered
Common stock, par value $0.001 per share	TDOC	The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On April 5, 2024, Teladoc Health, Inc. (“Teladoc Health” or the “Company”) announced that it continues to expect its outlook for the quarter ended March 31, 2024 and the year ending December 31, 2024 to be consistent with the outlook ranges disclosed in the Company’s earnings release on February 20, 2024. The financial results for the quarter ended March 31, 2024 are preliminary, unaudited and subject to change in connection with the completion of the Company’s financial closing process and the preparation of its financial statements for the quarter ended March 31, 2024.

The information in this Item 2.02 shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Executive Transition

On April 5, 2024, Teladoc Health announced the appointment of Mala Murthy to the position of acting Chief Executive Officer of the Company, effective immediately, replacing Jason Gorevic, who will also depart from the Board of Directors of the Company as required by his employment agreement. Following her appointment as acting Chief Executive Officer, Ms. Murthy will continue to serve as the Company’s Chief Financial Officer.

Ms. Murthy, 60, has served as the Company’s Chief Financial Officer since 2019, in which capacity she has led the Company’s global finance organization, including accounting, financial planning & analysis and investor relations. Previously, from 2016 to 2019, she served as Chief Financial Officer of Global Commercial Services at American Express, a financial services company, where she led strategic investment decisions and financial stewardship.

Except as otherwise disclosed in this current report, there are no arrangements or understandings between Ms. Murthy, on the one hand, and any other person, on the other hand, pursuant to which she was selected as an officer of the Company. Additionally, there are no family relationships between Ms. Murthy, on the one hand, and any director or officer of the Company, on the other hand, or any other related party transaction of the Company involving Ms. Murthy that would require disclosure under Item 404(a) of Regulation S-K.

Compensation Arrangements

In connection with her appointment as acting Chief Executive Officer, Ms. Murthy has entered into a letter agreement (the “Acting CEO Letter Agreement”) with the Company that provides that, while she serves as acting Chief Executive Officer, her base salary will be increased from $530,000 to approximately $750,000 and her target bonus opportunity will be increased from 75% to 120% of her base salary. In addition, Ms. Murthy will receive an additional annual equity grant with a target value of approximately $1,100,000 on the date of grant, which will be delivered as 50% time-vesting restricted stock units and 50% performance-vesting restricted stock units that will generally vest on the same schedule as her existing 2024 annual equity refresh grant.

The above summary does not purport to be a complete description and is qualified in its entirety by the Acting CEO Letter Agreement, a copy of which will be filed with the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024.

In connection with his separation, Mr. Gorevic will be eligible to receive the separation benefits pursuant to his employment agreement, subject to Mr. Gorevic’s execution and nonrevocation of a release of claims and other conditions of his employment agreement.

Item 7.01 Regulation FD Disclosure.

The Company’s press release regarding the executive transition described above is furnished herewith as Exhibit 99.1 and incorporated by reference herein.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933.

Cautionary Note Regarding Forward-Looking Statements

This report contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements the Company makes regarding future financial or operating results.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to its business model; (ii) changes in market conditions and receptivity to its services and offerings, including its ability to effectively compete; (iii) results of litigation or regulatory actions; (iv) the loss of one or more key clients or the loss of a significant number of members or BetterHelp paying users; (v) changes in valuations or useful lives of its assets; (vi) changes to its ability to recruit and retain qualified providers into its network; (vii) the impact of and risk related to impairment losses with respect to goodwill or other assets; and (viii) the success of its operational review of the Company to achieve a more balanced approach to growth and margin. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in its SEC reports, including, but not limited to, its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission.

Any forward-looking statement made by the Company in this report is based only on information currently available to it and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.						Description
99.1*						Teladoc Health, Inc. press release, dated April 5, 2024 .
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

*Furnished herewith.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 5, 2024


Teladoc Health, Inc.

By:			/s/ Adam C. Vandervoort
Name:			Adam C. Vandervoort
Title:			Chief Legal Officer and Secretary

EX-99.1 2 exhibit9911.htm EX-99.1 Document

Exhibit 99.1

Teladoc Health Board of Directors Announces Leadership Transition

•Jason Gorevic to depart the company, effective immediately

•CFO Mala Murthy appointed acting chief executive

•Teladoc Health reaffirms guidance

PURCHASE, NY, April 5, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today announced that Jason Gorevic is departing the company, effective immediately. The Board of Directors has appointed Mala Murthy acting Chief Executive Officer while it searches for Mr. Gorevic’s permanent successor. Ms. Murthy is a seasoned industry leader who has served as the Company’s Chief Financial Officer since 2019, and she will continue serving in this role during this transition period.

The Board has retained an executive search firm, which will evaluate internal and external candidates to identify Mr. Gorevic’s permanent successor.

“We thank Jason for his many achievements and contributions during the 15 years he led Teladoc Health. We wish him success in his future endeavors,” said David B. Snow, Jr., Chairman of the Teladoc Health Board of Directors. “We also thank Mala Murthy, a highly capable executive, for assuming the role of chief executive as we seek a permanent replacement. We are confident that this leadership transition will position the company for long-term success and value creation.”

Teladoc Health Reaffirms Guidance

In conjunction with this announcement, Teladoc Health reiterated its guidance for the first quarter and full year of 2024.

About Mala Murthy

With a focus on assuring shareholder value, Ms. Murthy is a seasoned leader with a proven track record of driving balanced top-and-bottom-line growth. She brings a passion for developing & implementing strategies that drive both short-term and long-term value, acquired from extensive financial management experience in diverse industries. Ms. Murthy has successfully overseen the development of capital structure and liquidity strategies.

Prior to joining Teladoc Health she held several senior executive positions at American Express, most recently as chief financial officer of the Global Commercial Services segment. There she led strategic investment decisions and P+L stewardship for the segment. She also previously served in various leadership positions with PepsiCo, leading high growth business units.

Ms. Murthy holds a bachelor's degree in computer science and engineering from Jadavpur University in India, an MBA from the India Institute of Management, and a master's degree in public and private management from Yale School of Management.

About Teladoc Health

Teladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Teladoc Health leverages more than two decades of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com.

Source: Teladoc Health, Inc. – General

Contact

PR@Teladochealth.com

(617) 444-9612

EX-101.SCH 3 tdoc-20240405.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 tdoc-20240405_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 5 tdoc-20240405_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Apr. 05, 2024
Cover [Abstract]
Document Type	8-K
Document Period End Date	Apr. 05, 2024
Entity Registrant Name	Teladoc Health, Inc.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-37477
Entity Tax Identification Number	04-3705970
Entity Address, Address Line One	2 Manhattanville Road
Entity Address, Address Line Two	Suite 203
Entity Address, City or Town	Purchase
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10577
City Area Code	203
Local Phone Number	635-2002
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common stock, par value $0.001 per share
Trading Symbol	TDOC
Security Exchange Name	NYSE
Entity Emerging Growth Company	false
Amendment Flag	false
Entity Central Index Key	0001477449

EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.teladoc.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tdoc-20240405.htm tdoc-20240405.xsd tdoc-20240405_lab.xml tdoc-20240405_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tdoc-20240405.htm": { "nsprefix": "tdoc", "nsuri": "http://www.teladoc.com/20240405", "dts": { "inline": { "local": [ "tdoc-20240405.htm" ] }, "schema": { "local": [ "tdoc-20240405.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "tdoc-20240405_lab.xml" ] }, "presentationLink": { "local": [ "tdoc-20240405_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.teladoc.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tdoc-20240405.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "tdoc-20240405.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.teladoc.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001477449-24-000083-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477449-24-000083-xbrl.zip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end XML 17 tdoc-20240405_htm.xml IDEA: XBRL DOCUMENT 0001477449 2024-04-05 2024-04-05 false 0001477449 8-K 2024-04-05 Teladoc Health, Inc. DE 001-37477 04-3705970 2 Manhattanville Road Suite 203 Purchase NY 10577 203 635-2002 false false false false Common stock, par value $0.001 per share TDOC NYSE false 2024-04-05